^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Hodgkin Lymphoma

    Related cancers:
    1d
    FIL_LymDeCo: Neurocognitive Assessment in Long-Term Survivors of Lymphoma (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Fondazione Italiana Linfomi - ETS
    New trial
    1d
    Immunogenomic profiles of HIV-associated classic Hodgkin lymphoma from Malawi. (PubMed, Blood Glob Hematol)
    TCR clonality was increased in EBV+ cHL, with trend towards further increase in clonality in HIV+. Through a multiomic approach of a well-characterized, HIV-inclusive cHL cohort from one of the most resource-limited countries in the world, we were able to recapitulate known, and identify novel molecular differences by HIV and EBV status.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8)
    3d
    Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Suspended, David Bond, MD | Recruiting --> Suspended
    Trial suspension
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    carboplatin • lenalidomide • cyclophosphamide • ifosfamide • etoposide IV • Monjuvi (tafasitamab-cxix)
    6d
    Relyage: Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=1, Completed, Centre Hospitalier Universitaire, Amiens | Recruiting --> Completed | N=114 --> 1
    Trial completion • Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • lenalidomide
    7d
    PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma (clinicaltrials.gov)
    P1/2, N=112, Not yet recruiting, Shanghai Jiao Tong University School of Medicine
    New P1/2 trial
    |
    AiRuiKa (camrelizumab) • AiSuDa (ivarmacitinib)
    8d
    Loss of systemic anti-viral immunity and LMP1-driven suppressive myeloid tumour niches converge to shape the immunobiology of Epstein-Barr virus-positive diffuse large B-cell lymphoma. (PubMed, Leukemia)
    Suppressive myeloid niches were preferentially enriched around LMP1-expressing tumour cells, a feature not observed in the other EBV-associated conditions. Together, these findings indicate that EBV⁺DLBCL is driven by the convergence of systemic antiviral immune dysfunction and an LMP1-dependent suppressive tumour microenvironment.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IDO1 (Indoleamine 2,3-dioxygenase 1)
    8d
    CD45BE-HSPC + CART-45 Cells (clinicaltrials.gov)
    P1, N=42, Recruiting, University of Pennsylvania | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • BCL6 (B-cell CLL/lymphoma 6) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    10d
    Pulmonary Sarcoidosis Associated With Pleural Effusion: A Case Report. (PubMed, Respirol Case Rep)
    The patient achieved complete clinical, biochemical and radiological remission following systemic corticosteroid therapy. This case highlights the importance of a rigorous differential diagnostic approach and careful clinicoradiological-histopathological correlation in rare presentations of sarcoidosis.
    Journal • Pleural effusion
    |
    IL2 (Interleukin 2)
    10d
    Utility of ultrasensitive, US Food and Drug Administration-approved κ and λ dual in situ hybridization assay in the diagnosis of Hodgkin lymphomas. (PubMed, Am J Clin Pathol)
    Although morphology and immunohistochemistry are usually sufficient to separate CHL from NLPHL, determining light chain restriction by K/L dual ISH could provide a valuable adjunct in challenging cases, potentially improving diagnostic accuracy and patient outcomes.
    FDA event • Journal
    |
    VENTANA HER2 Dual ISH DNA Probe Cocktail
    10d
    Novel therapeutic targets at the crossroad between epigenetics and signal transduction pathways in B-cell lymphomas. (PubMed, Clin Exp Med)
    This review explores the function of newly recognized kinases in lymphoma pathogenesis, such as CK1, CK2 and others, highlighting their interaction with epigenetic regulation. The therapeutic potential of targeting simultaneously signaling and epigenetic pathways is proposed as a potential innovative strategy in the treatment of lymphomas.
    Review • Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    13d
    NAHL: Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, University of Utah | Trial completion date: Apr 2028 --> Nov 2028 | Trial primary completion date: May 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Niktimvo (axatilimab-csfr)